Evidence map›Paper›PMID 35094801›Full record

SynthesisValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2022

Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.

Boshen Jiao, Anirban Basu, Scott Ramsey, Joshua Roth, M A Bender, Dalyna Quach, Beth Devine

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Boshen JiaoThe Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA.
Anirban BasuThe Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA; Department of Health Services, University of Washington, Seattle, WA, USA.
Scott RamseyThe Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA; Hutchinson Institute for Cancer Outcomes Research and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Joshua RothHutchinson Institute for Cancer Outcomes Research and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M A BenderDepartment of Pediatrics, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Dalyna QuachDepartment of Pharmacy, University of Washington, Seattle, WA, USA.
Beth DevineThe Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA; Department of Health Services, University of Washington, Seattle, WA, USA; Department of Biomedical Informatics, University of Washington, Seattle, WA, USA. Electronic address: bdevine@uw.edu.
University of Washington · USFred Hutch Cancer Center · US

Funding

Model for Economic Analysis of Sickle cell cURE (MEASURE)OT3HL152448 · NHLBI · UNIVERSITY OF WASHINGTON · PI BASU, ANIRBAN · 2019 to 2019
$3.3M
The Cure Sickle Cell Initiative Economic Analysis: An Evaluation of the Costs of Sickle Cell Disease and Potential Health Plan Budget Impacts of Gene Therapy as a New Treatment OptionOT3HL151434 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAMSEY, SCOTT D. · 2019 to 2019
$728k
NHLBI NIH HHS OT3 HL151434NHLBI NIH HHS OT3 HL152448
6 · The paper itself

Abstract

objectivesSickle cell disease (SCD) is a complex, chronic condition that impairs health-related quality of life of affected individuals and their caregivers. As curative therapies emerge, comprehensive cost-effectiveness models will inform their value. These models will require descriptions of health states and their corresponding utility values that accurately reflect health-related quality of life over the disease trajectory. The objectives of this systematic review were to develop a catalog of health state utility (HSU) values for SCD, identify research gaps, and provide future directions for preference elicitation.

methodsRecords were identified through searches of PubMed and Embase, Tufts Medical Center Cost-Effectiveness Analysis Registry, reference lists of relevant articles, and consultation with SCD experts (2008-2020). We removed duplicate records and excluded ineligible studies. For included studies, we summarized the study characteristics, methods used for eliciting HSUs, and HSU values.

resultsFive studies empirically elicited utilities using indirect methods (EQ-5D) (n = 3) and Short Form-6 Dimension (n = 2); these represent health states associated with general SCD (n = 1), SCD complications (n = 2), and SCD treatments (n = 3). Additionally, we extracted HSUs from 7 quality-adjusted life-years-based outcome research studies. The HSU among patients with general SCD without specifying complications ranged from 0.64 to 0.887. Only 36% of the HSUs used in the quality-adjusted life-year-based outcomes research studies were derived from individuals with SCD. No study estimated HSUs in caregivers.

conclusionsThere is a dearth of literature of HSUs for use in SCD models. Future empirical studies should elicit a comprehensive set of HSUs from individuals with SCD and their caregivers.

Indexed as

Quality of LifeAdultAnemia, Sickle CellAntisickling AgentsBlood TransfusionChildComorbidityCost-Benefit AnalysisFemaleHealth Status IndicatorsHumansHydroxyureaMaleOutcome Assessment, Health CarePainQuality-Adjusted Life YearsAntisickling AgentsHydroxyureacost-effectiveness analysishealth state utilitysickle cell diseasesystematic review

Identifiers

PMID35094801
PMCPMC8804335
OpenAlexW3197037774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.